San Francisco, CA, United States of America

Eric M Verdin

This inventor holds 23 USPTO granted patents and 8 published patent applications, plus 2 CIPO patents and 4 EPO patents, primarily in Drug Discovery. Top assignees: The J. David Gladstone Institutes, University of California, Ithaca College. Active years: 2006-2025.

IDiyas Innovation Intelligence. (2026). Inventor Profile: Eric M Verdin. Retrieved from https://idiyas.com/inventor/eric-m-verdin

Data source: USPTO (United States Patent and Trademark Office) public patent records. Weekly synchronization. How IDiyas builds this profile

USPTO Granted Patents = 23 (Patent Applications = 8)

% Patents Active = 78.3

CIPO Patents = 2

EPO Patents = 4 (Patent Applications = 7)

Average Co-Inventor Count = 2.8

ph-index = 4

Forward Citations = 60(Granted Patents)

Location History:

San Francisco, CA (US) (2006 - 2016)
Mill Valley, CA (US) (2018 - 2023)

Company Filing History:

17 out of 91

The J. David Gladstone Institutes

patents

10 out of 16,035

University of California

Buck Institute for Research on Aging

patents

5. 1 out of 159

Deutsches Krebsforschungszentrum

patents

6. 1 out of 538

Icahn School of Medicine at Mount Sinai

patents

7. 1 out of 1

Napa Therapeutics Limited

patent

where one patent can have more than one assignee

Years Active: 2006-2025

Loading Chart...

Areas of Expertise:

CD38 Inhibitors

Beta-Hydroxybutyrate

Butanediol

HIV Reporter System

Tauopathy Treatment

SIRT1 Modulation

Protein Acetylation

Tubulin Deacetylase

Histone Deacetylase

Immunogenic Compositions

NAD-Dependent Deacetylase

NF-KB Activity

23 patents (USPTO):Sort by Forward CitationsExplore Patents

1. 12509451 - Heteroaryl amide inhibitors of CD38 (2025-12-30),

2. 11773051 - S-enantiomers of beta-hydroxybutyrate and butanediol and methods for using same (2023-10-03),

3. 11608308 - Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same (2023-03-21),

4. 10889538 - Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same (2021-01-12),

5. 10647658 - Medium chain fatty acid esters of beta-hydroxybutyrate and butanediol and compositions and methods for using same (2020-05-12),

6. 10562839 - Medium chain fatty acid esters of β-hydroxybutyrate and butanediol and compositions and methods for using same (2020-02-18),

7. 10106818 - Dual-color HIV reporter system for the detection of latently-infected cells (2018-10-23),

8. 10004753 - Methods for treating tauopathy (2018-06-26),

9. 9474788 - Methods for the reactivation of latent HIV using cytosine methylation inhibitors and NF-KB activators (2016-10-25),

10. 8748464 - Use of SIRT1 activators or inhibitors to modulate an immune response (2014-06-10),

11. 8518635 - Regulation of protein activity by reversible acetylation (2013-08-27),

12. 8114853 - Methods of treating smooth muscle cell disorders (2012-02-14),

13. 7884081 - Methods of modulating tubulin deacetylast activity (2011-02-08),

14. 7745173 - Histone deacetylase and methods of use thereof (2010-06-29),

15. 7589167 - ZA loops of bromodomains (2009-09-15),

Title: Eric M. Verdin: Innovator in Biochemical Patents

Introduction

Eric M. Verdin is an accomplished inventor based in San Francisco, California, with a remarkable portfolio of 22 patents. His work primarily focuses on biochemical innovations, particularly in compounds that show promise for therapeutic applications.

Latest Patents

Among his latest contributions are noteworthy patents related to enantiomers of beta-hydroxybutyrate and butanediol. One patent details a compound comprising the enantiomerically enriched S-isomer S-BHB and S-1,3-butanediol, along with methods for its use. Another significant patent describes medium-chain fatty acid esters of beta-hydroxybutyrate and butanediol, including pharmaceutical compositions and methods for treating subjects through the administration of these esters.

Career Highlights

Eric has had a substantial impact in research through his affiliations with reputable institutions, notably the J. David Gladstone Institutes and the University of California. His contributions have advanced the understanding of biochemical applications and their potential in therapeutics.

Collaborations

Throughout his career, Eric has worked alongside distinguished colleagues, including Scott Michael Ulrich and John C. Newman. These collaborations have further enriched his research and invention processes, leading to significant advancements in their field.

Conclusion

Eric M. Verdin stands out as a prolific inventor shaping the landscape of biochemical patents. His innovative approaches and collaboration with top-tier institutions highlight the importance of teamwork in fostering groundbreaking advancements in science and medicine.

Profile summary based on public USPTO records.